Radko Komers

Company: Travere Therapeutics

Job title: Executive Director, Global Lead Clinical Development, Nephrology

Seminars:

From IgAN to FSGS: Translating Recent Successes & Lessons Learned to Beyond IgAN 9:30 am

Discuss how the FDA approval of sparsentan (Filspari) for IgA Nephropathy serves as a model for accelerating treatment development in other glomerular diseases, particularly FSGS Explore the ongoing FSGS trials and how lessons from the IgAN journey are being integrated to optimize clinical trial design and endpoint selection for rare glomerular diseases Highlight the role…Read more

day: Pre-Conference Focus Day